

International researchers test Creative Antibiotics substances on the *Pseudomonas* bacterium

The Umeå-based drug development company Creative Antibiotics, which is listed on the AktieTorget Equities Market Place, today announced that the company has signed a Material Transfer Agreement with the Université Catholique de Louvain in Brussels (Belgium), where researchers will test the company's substances on the *Pseudomonas* bacterium. The bacterium is potential lethal in burns patients and cause severe lung diseases in patients with COPD and cystic fibrosis.

Pseudomonas is what is known as an opportunistic bacterium, which attacks individuals whose immune defences are already weakened. As well as *Pseudomonas* being potentially lethal in patients with deep burns, it is one of the most troublesome bacteria in COPD (chronic obstructive pulmonary disease) and cystic fibrosis – where it causes lung diseases – and in deep burn wound infections.

"This agreement highlights the great potential and interest in our substances among researchers around the world," says Creative Antibiotics' CEO Ulf Boberg.

"The researchers at the Université Catholique de Louvain wish to use our target-seeking molecules to study whether and how these molecules can affect the ability of the bacterium to hide away in our cells, as well as whether the molecules can have an impact on the antibiotic treatment of intracellular *Pseudomonas*. The results of their experiments may greatly benefit the development work in the company's principal project, which is to develop drugs to treat *Pseudomonas* infections in deep burns."

The work also includes making a detailed study of the potential general synergy between Creative Antibiotics' substances and antibiotics on a large number of clinically relevant isolates, several of which are resistant to antibiotics. Creative Antibiotics has previously shown that these substances, one of which has gained Orphan Drug Designation, are effective against *Pseudomonas* in laboratory experiments.

Entering into the agreement with the Belgian university does not entail any costs for Creative Antibiotics. On the other hand, the company retains the commercial rights to the results of the project.

For further information, please contact

Ulf Boberg, CEO

Telephone: +46 733-12 44 90

E-mail: ulf.boberg@creativeantibiotics.com

www.creativeantibiotics.com

Notes for editors

The bacterium *Pseudomonas aeruginosa* and T3SS

Pseudomonas is often naturally resistant to antibiotics, and has several ways of protecting itself against these drugs. It has also been found that this bacterium can avoid the body's immune defences by hiding away inside our cells. This 'intracellular stage' has long been reported for a number of other pathogenic bacteria (*Salmonella*, *Chlamydia* and *Shigella*), and the type III secretion system, T3SS, has been found to play an important role in this. T3SS probably also plays a role for the intracellular form of *Pseudomonas*. T3SS is a system the bacteria have with which to infect our cells. Creative Antibiotics' substances specifically act on T3SS, and in so doing disarm the bacterium.

Om Creative Antibiotics Sweden AB

Creative Antibiotics Sweden AB is a drug development company formed in 2000 to commercialise world-leading research, principally at Umeå University and Karolinska Institutet. The company's substances, which are based on a revolutionary mechanism of action, have a unique ability to prevent the disease-causing properties of certain bacteria that have now become multiresistant from disrupting the normal bacterial flora. The development of resistance is minimised as a result. There is a great medical need for such drugs. Creative Antibiotics has three preclinical projects: infections in severe burns, an in-house project; diarrhoeal diseases, licensed to Syngene; sexually transmitted diseases, in cooperation with academic researchers. The company is listed on the AktieTorget Equities Market Place.